Willis Holloway, MD
Psychiatry · Oklahoma City, OKNPI 1023054434
Payments from drug & device makers
Across 528 payments — averaging $2638.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$336K
- Genentech, Inc.$234K
- AbbVie$164K
- F. Hoffmann-la Roche AG$160K
- Janssen Research & Development, LLC$152K
- Sunovion Pharmaceuticals Inc.$62K
- plus $284K from 22 others
What the payments were for
- Consulting fees$7201%
- Speaking & faculty fees$80,71888%
- Travel & lodging$5,7256%
- Food & beverage$4,4285%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 30 | $336,395 |
| Genentech, Inc. | 14 | $234,148 |
| AbbVie(2 entities) | 50 | $163,607 |
| F. Hoffmann-la Roche AG | 19 | $160,191 |
| Janssen Research & Development, LLC | 14 | $152,371 |
| Sunovion Pharmaceuticals Inc. | 7 | $62,122 |
| Otsuka America Pharmaceutical, Inc. | 108 | $55,881 |
| Pfizer | 30 | $52,128 |
| Shire North American Group Inc | 11 | $38,526 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $33,472 |
| Supernus Pharmaceuticals, Inc. | 49 | $26,158 |
| Eisai Inc. | 2 | $19,489 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $16,419 |
| Teva Pharmaceuticals USA, Inc. | 18 | $16,105 |
| Boehringer Ingelheim RCV GmbH & Co KG | 9 | $10,571 |
| Acadia Pharmaceuticals Inc | 9 | $7,625 |
| Johnson & Johnson | 56 | $3,520 |
| Boehringer Ingelheim | 8 | $3,392 |
| Vanda Pharmaceuticals Inc. | 15 | $255 |
| Lundbeck LLC | 11 | $226 |
| Tris Pharma Inc | 8 | $124 |
| Alkermes, Inc. | 4 | $101 |
| Corium, LLC | 1 | $92 |
| Neurocrine Biosciences, Inc. | 5 | $83 |
| Indivior Inc. | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$54,335
- QELBREE$22,214
- SPRAVATO$2,878
How this compares
$1,393,214 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 56 | $21,420 |
| Lisdexamfetamine Dimesylate | 55 | $11,130 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 267 | $7,647 |
| Clozapine | 122 | $7,579 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 55 | $4,509 |
| Naltrexone Hcl | 22 | $2,144 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 46 | $1,743 |
| Methylphenidate Hcl | 38 | $1,414 |
| Quetiapine Fumarate | 42 | $943 |
| Clonazepam | 87 | $608 |
| Carbamazepine ErCarbamazepine | 12 | $584 |
| Lurasidone Hcl | 16 | $574 |
| Lorazepam | 50 | $543 |
| Hydroxyzine Pamoate | 24 | $444 |
| Duloxetine Hcl | 12 | $410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $16,419 | $21,42056 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Oklahoma City
- Louise ThurmanOklahoma City$6.2M
- Veronique SebastianOklahoma City$3.8M
- Marvin PeytonOklahoma City$3.2M
- Courtney NixonOklahoma City$1.2M
- Surinder RandhawaOklahoma City$142K
- Adonis Al BotrosOklahoma City$73K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.